日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Muse-like stem cell therapy for curing chronic diseases in geriatric feline and canine

类似缪斯的干细胞疗法可用于治疗老年猫和犬的慢性疾病

Chen, Yu; Otsubo, Wataru; Li, Aoli; Hagino, Hirofumi; Liu, Aijie; Fan, Haishi; Huang, Chenwen

Cross-reactivity and sensitization profiles of cockroach and moth allergens provide new insights in cockroach-allergic patients

蟑螂和蛾类过敏原的交叉反应性和致敏性特征为蟑螂过敏患者提供了新的见解。

Zhang, Jiale; Li, Aoli; Liu, Li; Chang, Bo; Luo, Wenting; Sun, Baoqing

Reprogramming of human urine cells into cardiomyocytes via a small molecule cocktail in xeno-free conditions.

在无异种成分条件下,利用小分子混合物将人类尿液细胞重编程为心肌细胞

Chen Yu, Li Aoli, Liu Aijie, Zheng Wei, Fan Haishi, Zhang Jingwei, Huang Chenwen

Profile of cross-reactivity to common pollen allergens in Northwest China based on component resolved diagnosis

基于成分解析诊断的中国西北地区常见花粉过敏原交叉反应性概况

Li, Aoli; Huang, Zhifeng; Ye, Qingyuan; Zheng, Xianhui; Zhang, Jiale; Chen, Tong; Luo, Wenting; Sun, Baoqing

Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML)

发现一种高效激酶抑制剂,能够克服慢性粒细胞白血病 (CML) 的多种伊马替尼耐药 ABL 突变体

Tingting Lu, Jiangyan Cao, Fengming Zou, Xixiang Li, Aoli Wang, Wenliang Wang, Huamin Liang, Qingwang Liu, Chen Hu, Cheng Chen, Zhenquan Hu, Wenchao Wang, Lili Li, Jian Ge, Yang Shen, Tao Ren, Jing Liu, Ruixiang Xia, Qingsong Liu

Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia

基于原代细胞的网络分析揭示急性髓系白血病的药物反应状况

Cheng Chen, Li Wang, Lili Li, Aoli Wang, Tao Huang, Jie Hu, Ming Zhao, Feiyang Liu, Shuang Qi, Chen Hu, Wenliang Wang, Jing Liu, Jian Ge, Ruixiang Xia, Wenchao Wang, Qingsong Liu

Salviachinensines A-F, Antiproliferative Phenolic Derivatives from the Chinese Medicinal Plant Salvia chinensis

Salviachinensines AF,来自中药植物鼠尾草的抗增殖酚类衍生物

Qi Wang, Zhenquan Hu, Xixiang Li, Aoli Wang, Hong Wu, Jing Liu, Shugeng Cao, Qingsong Liu

Discovery of N-((1-(4-(3-(3-((6,7-Dimethoxyquinolin-3-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)propionamide (CHMFL-KIT-8140) as a Highly Potent Type II Inhibitor Capable of Inhibiting the T670I "Gatekeeper" Mutant of cKIT Kinase

发现 N-((1-(4-(3-(3-((6,7-二甲氧基喹诺林-3-基)氧基)苯基)脲基)-2-(三氟甲基)苯基)哌啶-4-基)甲基)丙酰胺 (CHMFL-KIT-8140) 是一种高效 II 型抑制剂,能够抑制 cKIT 激酶的 T670I“守门人”突变体

Binhua Li, Aoli Wang, Juan Liu, Ziping Qi, Xiaochuan Liu, Kailin Yu, Hong Wu, Cheng Chen, Chen Hu, Wenchao Wang, Jiaxin Wu, Zhenquan Hu, Ling Ye, Fengming Zou, Feiyang Liu, Beilei Wang, Li Wang, Tao Ren, Shaojuan Zhang, Mingfeng Bai, Shanchun Zhang, Jing Liu, Qingsong Liu